PATIENT-DERIVED ORGANOIDS CAPTURE HISTOLOGICAL, MOLECULAR AND THERAPEUTIC HETEROGENEITY IN PHARYNGEAL AND LARYNGEAL SQUAMOUS CELL CARCINOMAS

This study establishes a robust biobank of patient-derived organoids from pharyngeal and laryngeal squamous cell carcinomas that faithfully recapitulate the original tumors' histological and molecular heterogeneity, while demonstrating that prior therapy negatively impacts outgrowth and that these models can effectively predict differential therapeutic responses to cisplatin and radiation.

The Gist

The Big Idea: Growing "Mini-Tumors" to Fight Cancer

Imagine you are a chef trying to perfect a recipe for a very difficult dish. If you only taste the final meal, you might not know why it failed. But if you could grow a tiny, edible version of that dish in your kitchen, you could test different spices, temperatures, and cooking times without wasting the whole batch.

That is essentially what this research team did, but instead of food, they grew miniature versions of human throat and voice box cancers (called Patient-Derived Organoids or PDOs) in a lab.

The Problem: Guessing the Right Medicine

Head and neck cancer (like cancer of the throat or voice box) is tricky. Doctors often have to guess which treatment will work best. They might try a strong chemotherapy drug or radiation, but sometimes it doesn't work, or the cancer comes back. It's like trying to unlock a door with a key you aren't sure fits; you might break the lock (the patient's body) before finding the right key.

The Solution: The "Cancer Test Kitchen"

The researchers took tiny pieces of real tumors from patients and grew them in a special gel in the lab. These aren't just flat cells; they are 3D "mini-tumors" that look and act almost exactly like the real thing inside the human body.

Think of these organoids as living test dummies. Because they are made from the patient's own cells, they have the same "personality" and weaknesses as the original tumor.

What They Discovered

1. The "Freshness" Factor (Why some tumors are harder to grow)
The team tried to grow 180 mini-tumors. They found a surprising rule: The fresher the sample, the better.

• The Analogy: Imagine trying to start a campfire. If you use dry, fresh wood, it lights up easily. If the wood has been soaked in rain (chemotherapy or radiation) or left out in the sun for too long, it's very hard to get a flame going.
• The Finding: Patients who had already been treated with chemo or radiation before the sample was taken had much harder time growing these mini-tumors. The treatments had weakened the cancer cells so much they couldn't survive in the lab. This is a double-edged sword: it means we can't easily study "resistant" cancers this way, but it confirms that these treatments damage the cancer's ability to survive.

2. The HPV "Super-Sensitivity"
They found that tumors caused by the HPV virus (a common virus linked to throat cancer) were much easier to grow in the lab.

• The Analogy: Think of HPV-positive tumors as "high-maintenance" plants that are actually very fragile. When you put them in a controlled garden (the lab), they thrive. But when you hit them with a weed killer (chemo/radiation), they wilt very quickly.
• The Finding: In the lab, these HPV-positive mini-tumors died much faster when exposed to standard treatments than non-HPV tumors. This matches what doctors see in real life: HPV patients generally respond better to treatment.

3. The "Sleeping" Cancer (A New Discovery)
This is the most exciting part. The researchers looked at the genetic "blueprint" of these mini-tumors and found a group that didn't fit into any known category.

• The Analogy: Imagine a library where all the books are sorted by genre (Action, Romance, Sci-Fi). Suddenly, they find a book that looks like a thriller but has the quiet, slow pacing of a meditation guide. It's a "sleeping" book.
• The Finding: These specific mini-tumors were very quiet. They weren't growing fast (low activity), but they were very tough to kill with chemotherapy. They were like a turtle: slow to move, but with a shell so hard that standard weapons bounced right off. This explains why some patients' cancers come back even after treatment—they were hiding in a "sleeping" state that the drugs couldn't wake up and destroy.

4. The Perfect Match
The team checked if these mini-tumors actually looked like the real tumors.

• The Analogy: It's like making a 3D print of a statue. If you print it right, it should have the same cracks, curves, and details as the original.
• The Finding: The mini-tumors were almost identical to the real ones. They had the same layers, the same markers, and the same genetic code. This proves they are reliable models for testing new drugs.

Why This Matters

This study is a huge step forward for Precision Medicine.

Instead of giving every patient the same "one-size-fits-all" treatment, doctors could one day take a tiny piece of a patient's tumor, grow a mini-version in the lab, and test different drugs on it before giving it to the patient.

• "Hey, this drug killed the mini-tumor? Great, let's give it to the patient."
• "Oh, this drug didn't work? Let's try a different one."

The Bottom Line

The researchers built a massive library of "living test dummies" for throat and voice box cancers. They learned that:

1. Untreated tumors are easier to study in the lab.
2. HPV tumors are generally easier to kill.
3. There is a hidden, slow-moving type of cancer that is very hard to kill with current drugs, and we need to find new ways to wake it up and destroy it.

This work gives scientists a powerful new tool to stop guessing and start finding the right key for every patient's specific cancer lock.

Technical Summary

1. Problem Statement

Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous malignancy with poor survival rates (≈50% for advanced stages) and limited therapeutic options. While concurrent chemoradiotherapy (CRT) is the standard of care, many patients fail to respond, develop resistance, or relapse.

• Limitations of Current Models: Conventional 2D cell lines often lose tumor-specific genetic and phenotypic features over time. Murine models are costly, slow, and unsuitable for high-throughput screening.
• Unmet Need: There is a critical lack of robust, predictive biomarkers to guide treatment decisions. Existing Patient-Derived Organoid (PDO) collections are predominantly enriched for oral cavity tumors, leaving a gap in models for pharyngeal and laryngeal cancers, particularly regarding their ability to recapitulate stratified epithelium differentiation and HPV status.

2. Methodology

The study established and characterized a large biobank of HNSCC PDOs from fresh surgical and biopsy samples.

• Sample Collection: 180 fresh tumor samples were collected from 167 patients (2020–2024) at Hospital Universitario Central de Asturias (HUCA), covering laryngeal, hypopharyngeal, and oropharyngeal (HPV+ and HPV-) sites.
• Organoid Establishment:
  • Tissues were digested with trypsin and embedded in Matrigel.
  • Two expansion media were compared: HN (M0) (standard Driehuis protocol) and M7 (cervical SCC protocol). The study transitioned to M7 medium due to superior efficiency.
  • Organoids were passaged, cryopreserved, and recovered for long-term expansion.
• Characterization:
  • Histology/IHC: H&E staining and immunohistochemistry (Ki-67, p16, p63, CK13) were used to compare PDOs with original tumors.
  • Therapeutic Assays: PDOs were treated with cisplatin (dose-response) and ionizing radiation (4 Gy, 8 Gy), alone and in combination. Viability was measured via CellTiter-Glo 3D (ATP levels).
  • Transcriptomics: Bulk RNA sequencing (RNA-seq) was performed on 20 selected PDOs to analyze molecular subtypes and pathway enrichment.
  • In Vivo Validation: Xenografts were established in nude and B-NDG (ultra-immunodeficient) mice to assess tumorigenicity.
• Statistical Analysis: Multivariate logistic regression was used to identify independent predictors of organoid establishment success.

3. Key Contributions

• Largest Pharyngeal/Laryngeal PDO Biobank: Established 57 successfully expanded and cryopreserved PDO models, representing the largest collection specifically enriched for pharyngeal and laryngeal SCCs (previous major collections focused on oral cavity).
• Identification of Establishment Barriers: Identified prior chemotherapy and/or radiotherapy as the strongest independent negative predictor for organoid outgrowth, a finding with significant implications for generating therapy-resistant models.
• Discovery of a Novel Molecular Subtype: Transcriptomic analysis revealed a subset of PDOs that did not fit established HNSCC molecular subtypes (IMC1, IMC2, IMC3). This new group is characterized by low MYC and mTORC1 activity and is associated with high cisplatin resistance.
• Validation of Differentiation: Demonstrated that HNSCC PDOs faithfully recapitulate the stratified epithelium differentiation program (basal to differentiated states) of the original tumors.

4. Key Results

Establishment and Expansion

• Success Rates: Organoid formation occurred in 69% of samples; long-term expansion and cryopreservation were achieved in 32% overall (35% for samples with visible epithelial cells).
• Predictors of Success:
  • Negative: Prior treatment with CT/RT significantly reduced formation (33% vs 74-76%) and expansion (13% vs 34-47%).
  • Positive: HPV positivity was a strong independent predictor of expansion success (OR = 3.55). HPV+ tumors showed 100% formation and 50% expansion rates compared to HPV- tumors.
  • Anatomical Site: Hypopharyngeal tumors had lower efficiency (43%) compared to laryngeal/oropharyngeal (~70%).
• Medium Comparison: M7 medium yielded higher efficiency and smaller, more numerous organoids compared to the traditional HN (M0) medium, without altering molecular identity.

Histological and Molecular Concordance

• Differentiation: PDOs preserved the differentiation grade of the parent tumor (77% concordance in a subset of 13 pairs). HPV+ PDOs recapitulated features like koilocytes and high p16 expression.
• Molecular Subtyping:
  • Most PDOs clustered into known subtypes: IMC1 (HPV+, high proliferation), IMC2, and IMC3.
  • Novel Subtype: A distinct group (e.g., PDO_211, PDO_216) showed downregulation of MYC and mTORC1 pathways and reduced ATF4 activity. This suggests a quiescent phenotype.

Therapeutic Response

• Cisplatin & Radiation:
  • HPV+ PDOs were the most sensitive to both cisplatin (IC50 1–5 µM) and radiation.
  • HPV- PDOs showed variable resistance (IC50 >10 µM).
  • The novel "low MYC/mTOR" subtype exhibited the highest cisplatin resistance and was derived from patients with higher recurrence rates.
• Combination Therapy: Cisplatin (5 µM) acted as a radiosensitizer, but the effect was primarily additive rather than synergistic.
• Correlation: There was a trend (non-significant) linking cisplatin sensitivity to radiation sensitivity, supporting the use of induction chemotherapy response to stratify patients.

In Vivo Tumorigenicity

• PDOs successfully formed tumors in B-NDG mice (ultra-immunodeficient), but growth was inefficient in standard nude mice, highlighting the role of residual immune cells in clearance.
• Xenografts recapitulated the keratinization and stratification of the primary tumors.

5. Significance and Conclusion

• Precision Oncology Platform: This study validates HNSCC PDOs as a robust platform for functional precision oncology, capable of modeling the histological, molecular, and therapeutic heterogeneity of pharyngeal and laryngeal cancers.
• Clinical Implications:
  • Biopsy Timing: The strong negative impact of prior chemo/radiotherapy on organoid generation suggests that pre-treatment biopsies are essential for successful PDO biobanking and personalized drug testing.
  • Biomarker Discovery: The identification of a quiescent, MYC-low/mTOR-low subtype that is highly chemoresistant offers a new target for understanding treatment failure and recurrence.
  • HPV Status: Confirms HPV status as a key determinant of both organoid establishment success and therapeutic sensitivity.
• Future Directions: The authors advocate for prospective studies using pre-treatment biopsies to validate the predictive clinical value of PDOs in guiding treatment decisions for HNSCC patients.

Data Availability: The RNA-seq data is available in the GEO database under accession number GSE325165.